Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy

Objective To create an accurate pre-cystectomy decision-making tool that allows for the accurate identification of patients with clinically organ-confined urothelial carcinoma of the bladder (UCB) who have non-organ-confined UCB (NOC-UCB) at cystectomy, as identification of patients with UCB most likely to benefit from neoadjuvant chemotherapy (NACTx) is hampered by inaccurate clinical staging. Patients and Methods A prospectively maintained single-institution database containing 201 patients who underwent cystectomy and pelvic lymph node (LN) dissection without NACTx for UCB was analysed. Predictive variables for NOC-UCB included, among others, age, gender, transurethral resection of bladder tumour (TURBT) findings (stage, grade, histology, size, presence of carcinoma in situ, lymphovascular invasion [LVI], multifocality), history of intravesical therapy, time from TURBT to cystectomy, and cross-sectional imaging findings. Results Clinical stage distribution was 19 patients with Ta, 15 with Tis, 67 with T1, and 100 with T2. At the time of cystectomy, NOC-UCB and LN-positive disease were found in 71 (35%) and 38 (19%) of patients, respectively; 81 (40%) of patients had NOC-UCB (>= pT3/Nany or pTany/N+). Tumour stage (P [trend] < 0.001), presence of LVI (odds ratio [OR] 5.2; P = 0.02), and radiographic evidence of NOC-UCB or hydronephrosis (OR 3.2; P = 0.01) were independently associated with >= pT3 Nany UCB. Tumour stage (P [trend] < 0.001) and presence of LVI (OR 6.64; P = 0.01) were independently associated with (>= pT3/Nany or pTany/N+) UCB. A nomogram to predict (>= pT3/Nany or pTany/N+) based on all three variables was highly accurate (area under the curve 0.828) and well calibrated, deviating < 8% from ideal prediction. Decision curve analysis showed net benefit across all threshold probabilities. Conclusions NOC-UCB can be predicted with high accuracy by integrating standard clinicopathological factors with imaging information. This model may help to identify patients with NOC-UCB who may benefit from NACTx.